1. To assess levels of syndican-2 and syndican-3 in individuals with(T2DM)
2. To determine level of  syndican-2 and syndican-3 in patemt T2DM with complication
3. To assess the relationship between syndican-2 and syndican-3 and various biochemical markers .

1.  The study was conducted at the Department of Chemistry, College of Science for Women, University of Baghdad, and Al-Yarmouk Teaching Hospital, Iraq, from September to October 2025. Serum levels of Syndecan-2 and Syndecan-3 were measured using the enzyme-linked immunosorbent assay (ELISA) technique with a Human Reader HS. Glycated hemoglobin (HbA1c) was measured using a Siemens Healthineers analyzer. In addition, lipid profile parameters, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein cholesterol (VLDL-C), low-density lipoprotein cholesterol (LDL-C), and fasting blood glucose (FBG), were measured using a Huma Reader HS UV-Vis spectrophotometer (USA).

1. Measure levels of Syndecan-2 and Syndecan-3 as potential biomarkers for early endothelial damage in T2DM patients.
2. Stress on strict glycemic control especially HbA1c and a proper lipid management to decrease the endothelial glycocalyx damage and shed syndecans
3. To perform larger multicenter studies with a more diverse population to set reference ranges and cut-off values for Syndecan biomarkers.

4. Evaluate different glucose-lowering and lipid-lowering drugs on the levels of Syndecan and their impact on endothelial glycocalyx integrity.
5. Patients with T2DM should be encouraged to have a healthy lifestyle to reduce oxidative stress and diabetes related complications; including regular exercise and a balanced diet.

6.More research is required to understand the relationship between Syndecan biomarkers and the occurrence of chronic complications of diabetes such as cardiovascular           and renal diseases.